ArticleFrontiers in public health2025
Development and validation of a model to predict the risk of frailty in older adults with panvascular disease.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to identify factors influencing frailty in older adults with panvascular disease and to develop and validate a nomogram-based risk prediction model to support individualized frailty management. Methods: A total of 1,344 patients aged ≥60 years with panvascular disease were recruited using convenience sampling from March to December 2024. Participants were randomly divided into training and validation sets (7:3). Data included general characteristics, laboratory indices, and scores from the PSQI, ADL, GDS-15, and frailty assessments. Least absolute shrinkage and selection operator (LASSO) regression was used to select predictors, followed by multivariate logistic regression to construct the model. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), Hosmer-Lemeshow goodness-of-fit test, calibration curves, and decision curve analysis (DCA). Results: Among 1,344 participants, 366 (27.23%) were frail. LASSO regression identified increasing age, multiple atherosclerotic sites, elevated LDL-C, hypertension history, high HbA1c, and low ADL as significant predictors of frailty. The AUC values for the training and validation sets were 0.78 and 0.77, respectively, indicating good discrimination. The Hosmer-Lemeshow test ( Conclusion: The developed nomogram-based model demonstrates strong predictive performance and can objectively estimate frailty risk in older adults with panvascular disease, providing a basis for early screening and targeted prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.